Literature DB >> 7373292

Reduction and subsequent binding of ruthenium ions catalyzed by subcellular components.

M J Clarke, S Bitler, D Rennert, M Buchbinder, A D Kelman.   

Abstract

The reduction of Cl(NH3)5Ru(III) and subsequent binding of heterocyclic ligands by the resultant (H2O)(NH3)5Ru(II) ion is shown to be catalyzed by components of rat-liver cells. The presence of air significantly decreases the rate of heterocyclic ligand binding. In the case of microsome and soluble component catalysis, this is probably due to oxidation of the Ru(II) ion prior to complexation. Various inhibitors of electron-transfer proteins were employed in an effort to determine the preferred reducing species. These results lend support to the hypothesis that the antitumor activity of acido ruthenium(III) ammine complexes involves activation by reduction in vivo prior to metal coordination to nucleic acids. Anticancer drugs functioning by this mechanism may be preferentially toxic to or may localize in hypoxic areas of tumors.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7373292     DOI: 10.1016/s0162-0134(00)80045-8

Source DB:  PubMed          Journal:  J Inorg Biochem        ISSN: 0162-0134            Impact factor:   4.155


  9 in total

1.  Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy.

Authors:  Suzanne Leijen; Sjaak A Burgers; Paul Baas; Dick Pluim; Matthijs Tibben; Erik van Werkhoven; Enzo Alessio; Gianni Sava; Jos H Beijnen; Jan H M Schellens
Journal:  Invest New Drugs       Date:  2014-10-25       Impact factor: 3.850

2.  A newly synthesized molecule derived from ruthenium cation, with antitumour activity, activates NADPH oxidase in human neutrophils.

Authors:  M Carballo; R Vilaplana; G Márquez; M Conde; F J Bedoya; F González-Vílchez; F Sobrino
Journal:  Biochem J       Date:  1997-12-01       Impact factor: 3.857

3.  A novel ruthenium(II)-polypyridyl complex inhibits cell proliferation and induces cell apoptosis by impairing DNA damage repair.

Authors:  Qingyuan Yang; Zhao Zhang; Wenjie Mei; Fenyong Sun
Journal:  J Chemother       Date:  2013-12-06       Impact factor: 1.714

4.  Binding of the transition metal ion [(H2O)(NH3)5Ru(II)]2+ to nucleosomal core and internucleosomal DNA.

Authors:  K A Marx; R Kruger; M J Clarke
Journal:  Mol Cell Biochem       Date:  1989-04-11       Impact factor: 3.396

5.  Ruthenium ammine complexes as electron acceptors for growth stimulation by plasma membrane electron transport.

Authors:  J F Laliberté; I L Sun; F L Crane; M J Clarke
Journal:  J Bioenerg Biomembr       Date:  1987-02       Impact factor: 2.945

6.  Chelating agents in biological systems.

Authors:  J Schubert
Journal:  Environ Health Perspect       Date:  1981-08       Impact factor: 9.031

7.  Proteomic approaches in understanding action mechanisms of metal-based anticancer drugs.

Authors:  Ying Wang; Jen-Fu Chiu
Journal:  Met Based Drugs       Date:  2008

Review 8.  Challenges and opportunities in the development of metal-based anticancer theranostic agents.

Authors:  Shreyas P Vaidya; Shubhankar Gadre; Ravi Teja Kamisetti; Malay Patra
Journal:  Biosci Rep       Date:  2022-05-27       Impact factor: 3.840

Review 9.  Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems.

Authors:  Maria Grazia Ferraro; Marialuisa Piccolo; Gabriella Misso; Francesco Maione; Daniela Montesarchio; Michele Caraglia; Luigi Paduano; Rita Santamaria; Carlo Irace
Journal:  Cells       Date:  2020-06-05       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.